COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.

Aljabali, AAA; Bakshi, HA; Satija, S; Meenu,; Prasher, P; Ennab, RM; Chellappan, DK; Gupta, G; Negi, P; Goyal, R; Sharma, A; Mishra, V; Dureja, H; Dua, K; Tambuwala, MM

COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.

Aljabali, AAA Bakshi, HA Satija, S

Meenu, Prasher, P Ennab, RM Chellappan, DK Gupta, G Negi, P Goyal, R Sharma, A Mishra, V Dureja, H Dua, K

Tambuwala, MM

Permalink

Publisher:: Bentham Science Publishers Ltd.
Publication Type:: Journal Article
Citation:: Pharmaceutical nanotechnology, 2020, 8, (4), pp. 323-353
Issue Date:: 2020-01

Closed Access

	Filename	Description	Size
	A.A.A. Aljabali PNT MS w_d[1] (1).pdf	Published version	1.74 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Aljabali, AAA
dc.contributor.author	Bakshi, HA
dc.contributor.author	Satija, S https://orcid.org/0000-0003-4702-6534
dc.contributor.author	Meenu,
dc.contributor.author	Prasher, P
dc.contributor.author	Ennab, RM
dc.contributor.author	Chellappan, DK
dc.contributor.author	Gupta, G
dc.contributor.author	Negi, P
dc.contributor.author	Goyal, R
dc.contributor.author	Sharma, A
dc.contributor.author	Mishra, V
dc.contributor.author	Dureja, H
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Tambuwala, MM
dc.date.accessioned	2021-05-16T23:53:39Z
dc.date.available	2020-07-15
dc.date.available	2021-05-16T23:53:39Z
dc.date.issued	2020-01
dc.identifier.citation	Pharmaceutical nanotechnology, 2020, 8, (4), pp. 323-353
dc.identifier.issn	2211-7385
dc.identifier.issn	2211-7393
dc.identifier.uri	http://hdl.handle.net/10453/148925
dc.description.abstract	BACKGROUND:The newly emerged coronavirus SARS-CoV-2, first reported in December 2019, has infected about five and a half million people globally and resulted in nearly 9063264 deaths until the 24th of June 2020. Nevertheless, the highly contagious virus has instigated an unimaginably rapid response from scientific and medical communities. OBJECTIVES:Pioneering research on molecular mechanisms underlying the viral transmission, molecular pathogenicity, and potential treatments will be highlighted in this review. The development of antiviral drugs specific to SARS-CoV-2 is a complicated and tedious process. To accelerate scientific discoveries and advancement, researchers are consolidating available data from associated coronaviruses into a single pipeline, which can be readily made available to vaccine developers. METHODS:In order to find studies evaluating the COVID-19 virus epidemiology, repurposed drugs and potential vaccines, web searches and bibliographical bases have been used with keywords that matches the content of this review. RESULTS:The published results of SARS-CoV-2 structures and interactomics have been used to identify potential therapeutic candidates. We illustrate recent publications on SARS-CoV-2, concerning its molecular, epidemiological, and clinical characteristics, and focus on innovative diagnostics technologies in the production pipeline. This objective of this review is to enhance the comprehension of the unique characteristics of SARS-CoV-2 and strengthen future control measures. Lay Summary:An innovative analysis is evaluating the nature of the COVID-19 pandemic. The aim is to increase knowledge of possible viral detection methods, which highlights several new technology limitations and advantages. We have assessed some drugs currently for patients (Lopinavir, Ritonavir, Anakinra and Interferon beta 1a), as the feasibility of COVID-19 specific antivirals is not presently known. The study explores the race toward vaccine development and highlights some significant trials and candidates in various clinical phases. This research addresses critical knowledge gaps by identifying repurposed drugs currently under clinical trials. Findings will be fed back rapidly to the researchers interested in COVID 19 and support the evidence and potential of possible therapeutics and small molecules with their mode of action.
dc.format	Print
dc.language	eng
dc.publisher	Bentham Science Publishers Ltd.
dc.relation.ispartof	Pharmaceutical nanotechnology
dc.relation.isbasedon	10.2174/2211738508999200817163335
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.mesh	Animals
dc.subject.mesh	Antiviral Agents
dc.subject.mesh	Betacoronavirus
dc.subject.mesh	Coronavirus Infections
dc.subject.mesh	Drug Development
dc.subject.mesh	Drug Discovery
dc.subject.mesh	Drug Repositioning
dc.subject.mesh	Humans
dc.subject.mesh	Pandemics
dc.subject.mesh	Pneumonia, Viral
dc.subject.mesh	Viral Vaccines
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Pneumonia, Viral
dc.subject.mesh	Coronavirus Infections
dc.subject.mesh	Viral Vaccines
dc.subject.mesh	Antiviral Agents
dc.subject.mesh	Drug Discovery
dc.subject.mesh	Drug Repositioning
dc.subject.mesh	Pandemics
dc.subject.mesh	Betacoronavirus
dc.subject.mesh	Drug Development
dc.subject.mesh	Animals
dc.subject.mesh	Antiviral Agents
dc.subject.mesh	Betacoronavirus
dc.subject.mesh	COVID-19
dc.subject.mesh	COVID-19 Vaccines
dc.subject.mesh	Coronavirus Infections
dc.subject.mesh	Drug Development
dc.subject.mesh	Drug Discovery
dc.subject.mesh	Drug Repositioning
dc.subject.mesh	Humans
dc.subject.mesh	Pandemics
dc.subject.mesh	Pneumonia, Viral
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	Viral Vaccines
dc.title	COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
dc.type	Journal Article
utslib.citation.volume	8
utslib.location.activity	United Arab Emirates
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2021-05-16T23:53:35Z
pubs.issue	4
pubs.publication-status	Published
pubs.volume	8
utslib.citation.issue	4

Abstract:

BACKGROUND:The newly emerged coronavirus SARS-CoV-2, first reported in December 2019, has infected about five and a half million people globally and resulted in nearly 9063264 deaths until the 24th of June 2020. Nevertheless, the highly contagious virus has instigated an unimaginably rapid response from scientific and medical communities. OBJECTIVES:Pioneering research on molecular mechanisms underlying the viral transmission, molecular pathogenicity, and potential treatments will be highlighted in this review. The development of antiviral drugs specific to SARS-CoV-2 is a complicated and tedious process. To accelerate scientific discoveries and advancement, researchers are consolidating available data from associated coronaviruses into a single pipeline, which can be readily made available to vaccine developers. METHODS:In order to find studies evaluating the COVID-19 virus epidemiology, repurposed drugs and potential vaccines, web searches and bibliographical bases have been used with keywords that matches the content of this review. RESULTS:The published results of SARS-CoV-2 structures and interactomics have been used to identify potential therapeutic candidates. We illustrate recent publications on SARS-CoV-2, concerning its molecular, epidemiological, and clinical characteristics, and focus on innovative diagnostics technologies in the production pipeline. This objective of this review is to enhance the comprehension of the unique characteristics of SARS-CoV-2 and strengthen future control measures. Lay Summary:An innovative analysis is evaluating the nature of the COVID-19 pandemic. The aim is to increase knowledge of possible viral detection methods, which highlights several new technology limitations and advantages. We have assessed some drugs currently for patients (Lopinavir, Ritonavir, Anakinra and Interferon beta 1a), as the feasibility of COVID-19 specific antivirals is not presently known. The study explores the race toward vaccine development and highlights some significant trials and candidates in various clinical phases. This research addresses critical knowledge gaps by identifying repurposed drugs currently under clinical trials. Findings will be fed back rapidly to the researchers interested in COVID 19 and support the evidence and potential of possible therapeutics and small molecules with their mode of action.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/148925